Hepatocellular Carcinoma Clinical Trials

64 studies are recruiting for hepatocellular carcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

   The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric cancer and other GI malignancies is an area of great unmet need.…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   2 in total

   Run by

   Anwaar Saeed

   See if you can join NCT03539822 on ClinicalTrials.gov

2. A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

   This is a noninterventional, observational, long-term follow-up (LTFU) study. Patients in this study will be followed for 5 years from enrollment on this study to assess potential delayed risks of RPx products. Eligible participants for this LTFU study include patients who received at least 1 dose …

   Stage

   Not phased

   Ages

   18 and older

   Site

   UC San Diego Moores Cancer Center, La Jolla, California

   Locations

   2 in total

   Run by

   Replimune, Inc.

   See if you can join NCT06887348 on ClinicalTrials.gov

3. Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

   This is a single-arm, phase II study of patients with advanced liver cancer or hepatocellular carcinoma (HCC) who are eligible for first-line treatment with T300+D. The invesitgators hypothesize that T300+D will be safe and tolerated in CP-B patients with HCC. HCC mostly affects disadvantaged popul…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UT Health San Antonio, San Antonio, Texas

   Run by

   The University of Texas Health Science Center at San Antonio

   See if you can join NCT06526104 on ClinicalTrials.gov

4. Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

   This study will investigate if modulating the tumor microenvironment with biologic agents like XL-092 will have synergistic effect when combined with checkpoint based immunotherapeutic treatment of patients with hepatocellular carcinoma (HCC).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   3 in total

   Run by

   Anwaar Saeed

   See if you can join NCT06698250 on ClinicalTrials.gov

5. Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

   The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious diseases and possibly c…

   Stage

   Phase 1

   Ages

   Up to 21

   Site

   Houston Methodist Hospital, Houston, Texas

   Run by

   Baylor College of Medicine

   See if you can join NCT06198296 on ClinicalTrials.gov

6. The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

   The purpose of this research is to see the effect of triplet therapy with atezolizumab, bevacizumab, and memantine in treatment of your hepatocellular carcinoma.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Inova Schar Cancer Institute - Fair Oaks, Fairfax, Virginia

   Locations

   2 in total

   Run by

   Inova Health Care Services

   See if you can join NCT06789757 on ClinicalTrials.gov

7. Psychoeducational Intervention for Patients With Hepatocellular Carcinoma

   This study aims to refine and pilot test HARMONY, a psychoeducational intervention for patients with newly diagnosed hepatocellular carcinoma (HCC).

   Stage

   Not phased

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Run by

   Massachusetts General Hospital

   See if you can join NCT06541990 on ClinicalTrials.gov

8. A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

   Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   City of Hope /ID# 261468, Duarte, California

   Locations

   37 in total

   Run by

   AbbVie

   See if you can join NCT06109272 on ClinicalTrials.gov

9. Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

   This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   834 Medical Oncology Dept, Univ Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski" EAD, Sofia, Sofia,

   Locations

   32 in total

   Run by

   Can-Fite BioPharma

   See if you can join NCT05201404 on ClinicalTrials.gov

10. A Multicenter Cancer Biospecimen Collection Study

    This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent st…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Curebase, San Francisco, California

    Run by

    Cofactor Genomics, Inc.

    See if you can join NCT04510129 on ClinicalTrials.gov

11. A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

    This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic Phoenix, Phoenix, Arizona

    Locations

    10 in total

    Run by

    TORL Biotherapeutics, LLC

    See if you can join NCT06005740 on ClinicalTrials.gov

12. Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

    This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced solid malignancies. Patients will be screened and evaluated to determ…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    HonorHealth Research Institute, Scottsdale, Arizona

    Locations

    3 in total

    Run by

    BioEclipse Therapeutics

    See if you can join NCT04282044 on ClinicalTrials.gov

13. Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

    Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoembolization (TACE). We hypothesize that atezolizumab and be…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Houston Methodist Research Institute, Houston, Texas

    Run by

    The Methodist Hospital Research Institute

    See if you can join NCT05185505 on ClinicalTrials.gov

14. Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment

    The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other metastatic liver disease.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Tennessee Medical Center, Knoxville, Tennessee

    Run by

    University of Tennessee

    See if you can join NCT03686709 on ClinicalTrials.gov